全文获取类型
收费全文 | 190754篇 |
免费 | 34789篇 |
国内免费 | 2616篇 |
专业分类
耳鼻咽喉 | 5510篇 |
儿科学 | 6544篇 |
妇产科学 | 3550篇 |
基础医学 | 8736篇 |
口腔科学 | 2376篇 |
临床医学 | 30784篇 |
内科学 | 56020篇 |
皮肤病学 | 8197篇 |
神经病学 | 19149篇 |
特种医学 | 7723篇 |
外科学 | 46230篇 |
综合类 | 401篇 |
现状与发展 | 72篇 |
一般理论 | 19篇 |
预防医学 | 10100篇 |
眼科学 | 4062篇 |
药学 | 3599篇 |
1篇 | |
中国医学 | 90篇 |
肿瘤学 | 14996篇 |
出版年
2024年 | 551篇 |
2023年 | 5136篇 |
2022年 | 1954篇 |
2021年 | 4734篇 |
2020年 | 6928篇 |
2019年 | 3545篇 |
2018年 | 8927篇 |
2017年 | 8390篇 |
2016年 | 9584篇 |
2015年 | 9796篇 |
2014年 | 17372篇 |
2013年 | 18000篇 |
2012年 | 9182篇 |
2011年 | 9169篇 |
2010年 | 12139篇 |
2009年 | 15871篇 |
2008年 | 8702篇 |
2007年 | 6847篇 |
2006年 | 9022篇 |
2005年 | 6285篇 |
2004年 | 5132篇 |
2003年 | 3878篇 |
2002年 | 3745篇 |
2001年 | 3974篇 |
2000年 | 3127篇 |
1999年 | 3399篇 |
1998年 | 3902篇 |
1997年 | 3658篇 |
1996年 | 3536篇 |
1995年 | 3360篇 |
1994年 | 2076篇 |
1993年 | 1673篇 |
1992年 | 1444篇 |
1991年 | 1472篇 |
1990年 | 1110篇 |
1989年 | 1212篇 |
1988年 | 1044篇 |
1987年 | 879篇 |
1986年 | 910篇 |
1985年 | 739篇 |
1984年 | 579篇 |
1983年 | 536篇 |
1982年 | 548篇 |
1981年 | 422篇 |
1980年 | 379篇 |
1979年 | 315篇 |
1978年 | 339篇 |
1977年 | 408篇 |
1975年 | 283篇 |
1972年 | 309篇 |
排序方式: 共有10000条查询结果,搜索用时 929 毫秒
61.
Martín-Nares Eduardo Zuñiga-Tamayo Diego Hinojosa-Azaola Andrea 《Clinical rheumatology》2019,38(1):97-106
Clinical Rheumatology - We aimed to estimate the frequency of overlap of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) with systemic autoimmune diseases. Retrospective... 相似文献
62.
63.
64.
Devagi Kanakaraju Nurfatyha Rusydah bt Mohamad Shahdad Ying-Chin Lim Andrea Pace 《Sustainable Chemistry and Pharmacy》2019
The use of multifunctional materials for water remediation is a modern approach where adsorption phenomena and heterogeneous photocatalysis can be applied for the removal of pollutants. Since the ideal remediation system should be able to remove both organic and inorganic pollutants, a crucial aspect to consider is the knowledge of operational parameters affecting the removal process, especially when heavy metal ions are present in concoction as in real systems. Given the proven efficiency of multifunctional TiO2/Alg/FeNPs magnetic beads for the removal of model organic pollutants, this study investigated the possibility to exploit such system also for the removal of mixed heavy metals (MHM), specifically Cr(III), Cu(II), and Pb(II) ions, under ultraviolet irradiation at a wavelength of 254 nm. After a preliminary screening on the optimal catalyst loading, operating parameters such as the initial concentration of metal ions, contact and irradiation time, and pH were investigated to optimize the removal of metal ions using response surface methodology (RSM) via Box–Behnken design. Starting from a MHM solution containing 44 ppm of each metal ion, the removal of Pb(II), Cr(III), and Cu(II) ions in the aqueous solution was nearly completed (>98.4%) for all three ions within 72 min of irradiation at almost neutral pH (pH = 6.8). The stability of TiO2/Alg/FeNPs was confirmed by retrieving and reusing the beads in three consecutive cycles of heavy metals removal without observing significant changes in catalyst efficiency. 相似文献
65.
66.
Srdan Verstovsek MD PhD Jean-Jacques Kiladjian MD PhD Alessandro M. Vannucchi MD Ruben A. Mesa MD FACP Peg Squier MD PhD J. E. Hamer-Maansson MSPH Claire Harrison MD 《Cancer》2023,129(11):1681-1690
Background
In a pooled analysis of the phase 3 Controlled Myelofibrosis Study With Oral JAK Inhibitor Treatment I (COMFORT-I) and COMFORT-II clinical trials, adult patients with intermediate-2 or high-risk myelofibrosis who received oral ruxolitinib at randomization or after crossover from placebo or best available therapy (BAT) had improved overall survival (OS).Methods
This post hoc analysis of pooled COMFORT data examined relevant disease outcomes based on the disease duration (≤12 or >12 months from diagnosis) before ruxolitinib initiation.Results
The analysis included 525 patients (ruxolitinib: ≤12 months, n = 84; >12 months, n = 216; placebo/BAT: ≤12 months, n = 66; >12 months, n = 159); the median age was 65.0–70.0 years. Fewer thrombocytopenia and anemia events were observed among patients who initiated ruxolitinib treatment earlier. At Weeks 24 and 48, the spleen volume response (SVR) was higher for patients who initiated ruxolitinib earlier (47.6% vs. 32.9% at Week 24, p = .0610; 44.0% vs. 26.9% at Week 48, p = .0149). In a multivariable analysis of factors associated with spleen volume reduction, a logistic regression model that controlled for confounding factors found that a significantly greater binary reduction was observed among patients with shorter versus longer disease duration (p = .022). At Week 240, OS was significantly improved among patients who initiated ruxolitinib earlier (63% [95% CI, 51%‒73%] vs. 57% [95% CI, 49%‒64%]; hazard ratio, 1.53; 95% CI, 1.01‒2.31; p = .0430). Regardless of disease duration, a longer OS was observed for patients who received ruxolitinib versus those who received placebo/BAT.Conclusions
These findings suggest that earlier ruxolitinib initiation for adult patients with intermediate-2 and high-risk myelofibrosis may improve clinical outcomes, including fewer cytopenia events, durable SVR, and prolonged OS.Plain Language Summary
- Patients with myelofibrosis, a bone marrow cancer, often do not live as long as the general population. These patients may also have an enlarged spleen and difficult symptoms such as fatigue.
- Two large clinical trials showed that patients treated with the drug ruxolitinib lived longer and had improved symptoms compared to those treated with placebo or other standard treatments.
- Here it was examined whether starting treatment with ruxolitinib earlier (i.e., within a year of diagnosis) provided benefits versus delaying treatment.
- Patients who received ruxolitinib within a year of diagnosis lived longer and experienced fewer disease symptoms than those whose treatment was delayed.
67.
68.
69.
70.